Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

The stock's fall snapped a four-day winning streak.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases has fueled a 6% rise in its share price over the past ...